T
1.08
0.02 (2.38%)
| Penutupan Terdahulu | 1.05 |
| Buka | 1.05 |
| Jumlah Dagangan | 70,788 |
| Purata Dagangan (3B) | 185,603 |
| Modal Pasaran | 55,798,732 |
| Harga / Jualan (P/S) | 78.80 |
| Harga / Buku (P/B) | 4.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2026 |
| Margin Operasi (TTM) | -10,800.00% |
| EPS Cair (TTM) | -0.440 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 116.57% |
| Nisbah Semasa (MRQ) | 3.11 |
| Aliran Tunai Operasi (OCF TTM) | -13.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.73 M |
| Pulangan Atas Aset (ROA TTM) | -39.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Talphera, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.3 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -1.5 |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.15 |
|
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.64% |
| % Dimiliki oleh Institusi | 31.31% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |